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Background: Antiretroviral therapy (ART) is known to save lives. Among HIV-infected infants living in resource
constrained settings, the short and long term benefits of ART are only partially known. This study was designed to
determine the virologic, immunologic and clinical outcomes of antiretroviral therapy in a cohort of HIV-infected
infants receiving care from an outpatient clinic in Kampala, Uganda.
Methods: A prospective cohort of HIV-infected infants receiving treatment at the Baylor-Uganda clinic was
analyzed. Patients were diagnosed, enrolled and followed up at the clinic. HIV viral load, CD4 cell counts and
clinical progress were assessed during follow-up. Descriptive statistical analysis and logistic regression modeling to
determine predictors of treatment success were conducted.
Results: Of 91 HIV-infected infants enrolled into the cohort, 53 (58.2%) infants were female; 43 (47.3%) were
6 months of age or younger, and 50 (55.6%) had advanced HIV/AIDS disease (Clinical stage 3 or 4). Eighty four
infants started ART and 78 (92.9%) completed 6 months of treatments. Fifty six (71.8%) infants attained virologic
suppression by month-6 of ART, and at month-12 of ART, the cumulative probability of attaining viral suppression
was 83.1%. None of the baseline infant factors (age, sex, WHO stage, CD4 cell percent, weight for age, or height for
age z-score) predicted treatment success. There was an increase in CD4 cells from a baseline mean of 23% to 30%
at month-6 of treatment (p<0.001) and by month-24 of ART, the mean CD4 percent was 36%. A total of 7 patients
died while on ART and another 7 experienced adverse events that were related to treatment.
Conclusion: Our results show that, even among very young patients from resource constrained settings, ART
dramatically suppresses HIV replication, allows immune recovery and clinical improvement, and is safe. However,
baseline characteristics do not predict recovery in this age group.
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Over the last decade, the beneficial effects of antiretro-
viral therapy (ART) have been reported among HIV-
infected adults and children in both resource rich and
resource poor countries [1-4]. Antiretroviral therapy
markedly reduces morbidity and mortality by suppress-
ing viral replication which ultimately leads to immune
recovery and a reduction in opportunistic infections.* Correspondence: vtukei@baylor-uganda.org
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reproduction in any medium, provided the orAmong infants and children, early introduction of ART
is known to save lives [5-7]. However, the effects of early
initiation of life-long treatment among infants receiving
care in HIV treatment programs in the resource
constrained settings of Africa are not fully known.
The World Health Organization (WHO) in its 2010
revision of HIV treatment guidelines recommends early
initiation of ART among infants and young children [8].
As these recommendations are being implemented
across Africa, a sizable number of HIV-infected infants,
some as young as 6 weeks, are being started on these
daily medications. The short and long term effects oftd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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are yet to be fully known. The frequency of adverse
events among these infants, and the level of immuno-
logic and clinical recovery that occurs when these drugs
are administered to infants outside of the controlled en-
vironment of clinical trials are yet to be determined.
The objective of this study was to determine the viro-
logic response to ART in a cohort of HIV-infected
Ugandan infants (children less than 12 months of age)
as measured by HIV viral suppression after 6 months of
therapy; determine the level of immunologic recovery as
measured by increase in CD4 cell counts; and determine
the proportion of infants developing ART-related ad-
verse events.
Methods
Study design and setting
For this observational cohort study, we recruited and
followed HIV-infected infants who were enrolling for care
and treatment at the Baylor College of Medicine Bristol
Myers Squibb Children’s clinical centre of excellence at
Mulago Hospital (Baylor-Uganda) in Kampala, Uganda.
Baylor-Uganda is a Non Governmental Organization
(NGO) involved in the prevention, care and treatment of
HIV-infected children and their families in Uganda. The
Foundation is donor funded and runs a clinic that offers
free clinical care to all its patients. The clinic is an out-
patient treatment center that operates five days a week
with an average daily attendance of 170 patients. Over
90% of patients seen at the clinic are children from the
age of 6 weeks to 18 years. Parents or adult caretakers
constitute the remainder of the patients.
At the clinic, patient care involves HIV diagnosis and
treatment, nutritional rehabilitation, diagnosis and treat-
ment of opportunistic infections, counseling and social
support. Infants enrolled for care at the clinic are referred
from the nearby Mulago National Referral hospital wards
and from other centers involved in Prevention of Mother
to Child HIV Transmission (PMTCT). Some infants are
referred from HIV treatment centers within the country,
and others are self referrals.
Study participants
Study participants were identified and recruited into the
cohort from the Baylor-Uganda clinic patient population.
Study participants were selected based on a criteria that
required them to be clinic patients, confirmed to be HIV
positive (by 2 positive blood tests showing the presence
of viral nucleic acids in the patient’s blood samples); be-
tween 6-weeks and 12 months of age; ART naïve, but
willing to start ART as soon as deemed necessary by the
clinician; reside within 20 kilometer radius from the
clinic; willing to be visited at home; and agree to be
regularly followed-up at the clinic. Children withoutparents or guardians were excluded. Patients less than
6 weeks of age were not included since they were not
routinely registered for care at the clinic. Based on
WHO guidelines for infant diagnosis [9], and recom-
mendations from the Ugandan Ministry of Health, rou-
tine diagnosis of HIV at Baylor-Uganda is carried out
from the age of 6 weeks when infants are brought back
to hospital for immunization.
From April 2009 to March 2012, all clinic patients that
fulfilled the selection criteria were consecutively recruited
into the cohort and were subsequently followed up.Follow-up procedures and variables measured
Before starting ART, we confirmed HIV infection in the
infants by carrying out an HIV DNA Polymerase Chain
Reaction (PCR) test followed 2 weeks later by a viral
RNA PCR test to quantify the HIV virus in the blood.
To be considered HIV infected, both tests had to con-
firm presence of the virus in blood.
All laboratory- confirmed HIV infected infants were
started on ART. Infants enrolled before July 2010 were
started on ART based on the 2006 WHO guidelines for
ART initiation. Based on these guidelines, all infants
with CD4 cell counts below 25% or in advanced WHO
clinical stages (stages 3 and 4) were considered eligible
for ART and were started on treatment. Following the
2010 revision of WHO treatment guidelines, all HIV-
infected infants were started on ART irrespective of their
clinical stage or CD4 cell counts. A combination of 2
Nucleoside Reverse transcriptase inhibitor (NRTI) drugs
and 1 Non-Nucleoside Reverse Transcriptase (NNRTI) or
Protease Inhibitor was the ART combination of choice.
Zidovudine (ZDV) or stavudine (D4T) combined with
lamivudine (3TC) together with either nevirapine (NVP)
or Lopinavir/ritonavir were the main ART drug combina-
tions as recommended by WHO. Stavudine was preferred
in patients with anemia (hemoglobin <7.5 g/dl) and
Lopinavir/ritonavir was preferred in patients exposed to
single dose NVP for PMTCT. Patients on rifampicin for
treatment of tuberculosis were put on 3 NRTIs (ZDV or
D4T + 3TC + Abacavir).
Baseline measurements and tests were carried out on
the date when ART was started and subsequent follow-
up visits were scheduled 2, 4, and 8 weeks after starting
treatment. Thereafter, patients returned to the clinic
monthly, and if an appointment was missed, a home visit
was carried out by trained home health workers. In
addition, parents were encouraged to bring the children
for medical care whenever they fell sick. At baseline and
every 6 months thereafter, blood samples were drawn for
complete blood count (CBC), CD4 cell count; liver func-
tion test [serum alanine amino transferase (ALT)], and
HIV viral load.
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mented and managed any adverse events or opportunistic
infections. In addition, nutritional assessment including
measurement of weight and height was conducted.
Anthropometric computations and comparisons were
conducted using the WHO anthro software [10] which is
based on WHO child growth standards. Underweight was
defined as a weight for age z-score (WAZ-score) less than
-2 standard deviations (SD) from the WHO reference me-
dian values. Stunting was defined as height for age z-score
(HAZ-score) less than -2SD from the reference values and
weight for height z-score (WHZ-score) less than -2SD
from the WHO reference median defined wasting. Adher-
ence to medication was encouraged by both the physician
and a trained counselor.
Antiretroviral therapy was considered the exposure
variable and the primary outcome variable was viral sup-
pression 6 months after ART initiation. Other outcomes
of interest included change in CD4 cell count; occu-
rrence of ART-related adverse events; death during
follow-up; and change in nutritional status as measured
by weight-for-age, height-for-age and weight for height
z-scores. Virologic suppression was defined as the attain-
ment of HIV viral loads less than 400 copies/ml after
6 months of ART.
Patients’ age, sex, WHO clinical stage, ART combin-
ation, presence of opportunistic infections and concur-
rent use of other medication, were considered potential
confounders and were therefore documented and con-
sidered in the analysis.
All patient information was recorded in structured
forms and was subsequently entered into the clinics
electronic medical database which is designed to check
for consistency of the data.
Written approval to conduct the study was granted by
Makerere University College of Health Sciences’ Re-
search and Ethics committee, Uganda National Council
of Science and Technology, and Baylor College of Medi-
cine Institutional Review Board (USA). The parents or
caretakers gave written informed consent to participate
in the study.
Statistical analysis
Descriptive analyses of baseline and follow-up characteris-
tics are presented as proportions, medians with inter-
quartile ranges (IQR), and means with standard deviations
(SD).We used the paired t-test to compare the mean CD4
cell counts at baseline and during follow-up. Virologic
suppression was categorized as ‘successful’ for viral loads
less than 400 copies per milliliter and as ‘unsuccessful’ if
otherwise. We used bivariate and multivariable logistic
regression models to identify predictors of successful
virologic suppression. Proportions of infants developing
ART related adverse events were computed. For allanalyses, confidence intervals (CI) were set at the 95%
level and p-values less than 0.05 were considered statisti-
cally significant.
Results
Of 91 HIV-infected infants enrolled into the cohort dur-
ing the study period, 53(58.2%) patients were female; 43
(47.3%) were 6 months of age or younger, and 57
(62.7%) were moderate or severely underweight (Table 1).
The median time from initial registration at the clinic to
ART initiation was 57 days (IQR: 34.5-89). This duration
varied according to ART initiation guidelines used at the
clinic. The median time to ART initiation for patients
that were started based on 2006 WHO treatment guide-
lines was 69 days (IQR=47-115); whereas the duration to
ART initiation for patients that were started based on
the revised 2010 guidelines was 33 days(IQR=28-44).
The median follow-up time after initiating ART was
752 days (IQR= 531-980). The median age at ART initi-
ation was 28.3 weeks (IQR=19.7-39) for infants started
under the 2006 guidelines and 22.6 weeks (IQR=17.1-
34.7) for infants that were started under 2010 WHO
treatment guidelines.
During the follow-up period, a total of 84 patients
were started on ART; 59 (70.2%) infants were started
based on the 2006 WHO treatment guidelines and 25
(29.8%) were started based on the revised 2010 treat-
ment guidelines. Seven infants were not started on treat-
ment because 4 of them died shortly after enrolment
and 3 were lost to follow-up before ART could be initi-
ated. Among infants that started ART, 78 (92.9%) were
in active care at the end of the first 6 months of therapy;
4 patients died and 2 were lost to follow-up within the
6 month period. At the end of the study period, 70, 62
and 47 patients had received ART for at least 12, 18 and
24 months respectively.
Virologic response
Of the 78 infants that had ART for at least 6 months,
successful viral suppression was seen in 56(71.8%) in-
fants. Twenty two (28.2%) infants continued to have de-
tectable viremia at month-6 of treatment. In univariate
and multivariable regression analysis; none of the base-
line factors such as age, gender, CD4 cell percent, WHO
clinical stage, choice of antiretroviral agent, weight for
age or height for age z-scores could predict treatment
success at month-6 of therapy (Table 2).
At month-12 of ART, 8 of the 22 patients that had de-
tectable viremia at month-6, attained viral suppression; 1
patient got lost to follow-up, 1 was switched to second
line ART, and 12 patients continued to have detectable
viremia. On subsequent clinic visits, 6 of the 12 patients
were switched to second-line ART, 4 were lost to follow-
up and 2 died (Table 3). Among patients that attained
Table 1 Baseline characteristics of a cohort of 91 HIV-
infected infants followed up at Baylor-Uganda
Variable Median (IQR) N (%)























Median (IQR) −2.2 (-3.89 - -1)
<-3SD score 33 (36.3)
≥-3SD to <-2SD 24 (26.4)
≥-2≤SD to < -1SD 11 (12.1)
≥-1SD 23 (25.2)
Height/Age z-score
Median −1.92 (-3.05 - -1.02)
<-3SD score 23 (25.3)
≥-3SD to<-2SD 20 (21.9)
≥-2SD to<-1SD 26 (28.6)
≥-1SD 22 (24.2)
IQR= Inter-quartile range, SD= standard deviation, WHO= World Health
Organization, ART=antiretroviral therapy, ZDV=zidovudine, 3TC=lamivudine,
D4T=stavudine, NVP=nevirapine, Lop/r= Lopinavir/ritonavir.
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at month-12 of ART.
Of 47 patients that completed 24 months of ART; 44
(93.6%) were still on first line treatment. Of these, 37
(84.1%) continued to have viral suppression; and 7 pa-
tients had detectable viremia, all of whom had earlier
achieved viral suppression.Altogether 7 patients were switched to second-line
treatment (Abacavir + 3TC + Lopinavir/ritonavir) as a
result of persistent viremia;5 out of the 7 attained viral
suppression 6 months after starting second-line ART,
and 2 patients were yet to complete 6 months of
second-line ART.
The cumulative probabilities of attaining viral suppres-
sion at month-6 and month-12 of ART were 71.8% (95%
CI: 61.6-81.3) and 83.1% (95% CI: 73.8-90.5) respectively.
The choice of third agent (Nevirapine versus Lopi-
navir/r) was not associated with risk of viremia at
month-6, even after adjusting for the choice of NRTI
backbone and baseline WHO clinical stage, Risk Ratio
(RR)=1.1 (95% CI: 0.8-1.5), P=0.152. There was no asso-
ciation between WHO guideline used for patient treat-
ment (2006 versus 2010) and risk of virologic failure at
month-6 of ART; RR=1.24 (95% CI: 0.9-1.6).
Immunologic response
There was a significant increase in CD4 cells from a base-
line mean of 23% (SD=10.1) to 30% (SD=9.6) at month-6,
P<0.001; and to 33% (SD=8.9) at month-12 of ART;
(P=0.009, for the change between month-6 and month-12).
By the end of the second year of ART, the mean CD4 cell
percentage rose to 36% (SD=8.05) (Figure 1). The propor-
tion of infants with very low CD4 cell counts (<15%)
dropped from 23.8% at baseline to 8.5% at 6 months of
treatment, and by the end of the second year, only one
patient continued to have CD4 cell percentage below 15%.
This patient was an infant, with no prior exposure to nevi-
rapine for PMTCT, who started ART (D4T+3TC+NVP) at
the age of 4 months with a baseline CD4 of 16%. His CD4
percentage dropped to 15% at month-6 and to 14% at
month-24 of ART. He never attained virologic suppression
and was considered a case of treatment failure due to
possible primary HIV resistance. He was subsequently
started on second-line ART.
Clinical response
Ten (11.9%) of the 84 patients that started ART were di-
agnosed with tuberculosis at baseline or shortly after
ART initiation. Anti-tuberculosis treatment was started
but one patient died after 5 months of ART and tubercu-
losis medication. One 7-month old infant was diagnosed
with disseminated Bacillus Calmette-Guerin (BCG) in-
fection 3 months after starting ART. He was treated as a
case of immune reconstitution inflammatory syndrome
(IRIS) and improved.
At ART initiation, 54 (64.3%) of 84 patients had a
WAZ-score below -2SD of the WHO reference median.
This prevalence of underweight varied according to age
and clinical stage of the disease. Thirty six (80%) of 45
older infants (7-12 months of age) compared to 18
(46.2%) of 39 younger infants (1-6 months of age) were
Table 2 Baseline predictors of treatment success (viral load<400 copies) among HIV-infected infants 6 months after
ART initiation
Characteristic Univariate OR P-value Multivariable OR P-value
(95% CI) (95% CI)
Age (>6 months) 0.83 (0.31-2.24) 0.718 1.20 (0.33-4.37) 0.785
Sex (Male) 1.01 (0.37-2.74) 0.990 0.77 (0.24-2.45) 0.657
CD4 percent (every 1%) 0.99 (0.94-1.04) 0.670 0.95 (0.89-1.01) 0.123
WHO stage (stage3&4) 0.43 (0.15-1.23) 0.116 0.33 (0.08-1.14) 0.078
Protease Inhibitor 1.34 (0.45-4.02) 0.603 1.33 (038-4.65) 0.657
Weight for Age Z-score (<-2) 0.63 (0.21-1.85) 0.395 0.40 (0.09-1.76) 0.227
Height for age Z-score (<-2) 1.44 (0.50-4.12) 0.500 2.08 (0.58-7.47) 0.260
ART= antiretroviral therapy; OR= Odds Ratio; CI= Confidence Interval; WHO= World Health Organization.
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1.19-2.51). Of 47 infants with baseline advanced HIV
disease (WHO clinical stage 3&4), 36 (76.6%) were
underweight; and among 37 infants with milder clinical
disease (WHO clinical stage 1&2), 18 (48.6%) were
found to be underweight at baseline; prevalence ratio=
1.6 (95% CI: 1.09-2.27). There was no association be-
tween baseline underweight and gender or baseline CD4
cell counts.
Among the 78 infants that received ART for at least
6 months, the proportion that were underweight re-
duced from 65.4% at baseline to 30.8% at 6 month of
ART, p<0.001
Eighty one patients were included in the analysis of
height for age z-scores (HAZ-score). Of these, 32Table 3 Characteristics of 12 children with virologic treatmen















WHO= World Health Organization; ART= Antiretroviral therapy; OI= opportunistic in(39.5%) patients had baseline HAZ-score less than -2.
Twenty (46.5%) out of 43 infants aged 6-12 months
compared to 12 (31.5%) out of 38 infants younger than
6 months of age were stunted; prevalence ratio=1.5 (95%
CI: 0.84-2.60). Twenty three (51.1%) of 45 patients in
WHO stage 3or 4 compared to 9 (25%) of 36 patients in
WHO stage 1 or 2 were stunted at baseline; prevalence
ratio=2 (95% CI: 1.08-3.85).
There was no significant change in stunting in the first
6 month of ART. Of 75 patients that had both baseline
and follow-up HAZ-score measurements, the prevalence
of stunting increased from 40% at baseline to 48% after
6 months of ART, p=0.134.
Of 65 patients that were included in the analysis of
weight for height z-scores (WHZ-score), 22 (33.8%) hadt failure after 12 months of antiretroviral therapy
ART regimen Other significant
OIs/social issues
Outcome
ZDV-3TC-NVP None Lost to follow-up




Switched to second line
ART
D4T-3TC-ABC Tuberculosis Died
ZDV-3TC-ABC Tuberculosis Lost to follow-up
D4T-3TC-NVP Chronic suppurative
otitis media
Switched to second line
ART
D4T-3TC-NVP None Lost to follow-up
ZDV-3TC-NVP None Switched to second line
ART
D4T-3TC-NVP Poor adherence to
ART
Switched to second line
ART
D4T-3TC-LPV/r Teenage Mother Lost to follow-up


















Figure 1 Change in CD4 cell counts in a cohort of children
receiving antiretroviral therapy at Baylor-Uganda.
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months of ART, only 9 (13.8%) patients continued to
have WHZ-scores less than -2; p=0.007.
Deaths and other adverse events
A total of 11 (12.1%) patients died during the follow-up
period. Four of the 11 died before ART could be initi-
ated. All 4 patients were in WHO clinical stage 4; be-
tween 6-12 months of age at the time of death; and had
been in care for 6-11.7 weeks. The illness preceding
death was tuberculous pericarditis for one female infant,
dysentery and lymphoma for other 2 female infants and
Pneumocystis Jirovecii Pneumonia for the only male in-
fant. Of the 7 infants that died while on ART, 4 died
within the first 6 months, 1 died in the 8th month and 2
died in the second year of ART. The overall mortality
rate among children on ART was 4.09 (95% CI: 1.95-
8.58) per 100 child-years. Post mortem examinations
were not carried out; however, the majority of patients
that died had underlying malnutrition (Table 4).
Within the first 6 months of ART, adverse events were
reported in 7 (8.3%) of the 84 patients that started treat-
ment. Of the seven, 3 patients developed diarrhea, 1 had
nausea and vomiting, 2 had anemia and 1 developed a
skin rash. One of the 3 infants with diarrhea and the oneTable 4 Characteristics of 7 HIV-infected Children that died w




1 7 Male 3
2 7 Female 4
3 6 Female 3
4 7 Male 4
5 11 Male 4
6 7 Female 3
7 10 Male 4
ART= Antiretroviral therapy; WHO= World Health Organization; D4T= Stavudine; 3TCinfant with nausea and vomiting were on a PI based
regimen. All patients with anemia were on ZDV and the
one patient with skin rash was on nevirapine. All
patients that developed anemia or skin rash had ART
regimen change. Patients with diarrhea, nausea and
vomiting had mild and transient illness not requiring
ART regimen change.
Discussion
In this study, which involved a cohort of HIV-infected
infants receiving first-line antiretroviral therapy in an
outpatient setting in Uganda, we found that 71% of in-
fants attained virologic suppression by 6 months of
ART. In general, the infants had good immune recovery
and experienced low levels of drug toxicity, with only 8%
of patients reporting adverse events during the study
period. Our results show that, even among very young
infants from resource constrained settings, ART dramat-
ically suppresses HIV replication, allows immune recov-
ery and clinical improvement, and is safe.
In sub-Saharan Africa, the treatment of HIV-infected
infants has lagged behind that of older children and
adults largely as a result of delays in diagnosis [11], re-
stricted choice of ART, lack of appropriate drug formu-
lations and inadequate levels of trained medical
personnel [12,13]. These difficulties coupled with the
high rates of viral resistance among infants that received
nevirapine for PMTCT, complicate the attainment of
treatment success [14,15]. However, despite these chal-
lenges, the majority of infants in our cohort were ad-
equately able to suppress the virus, increase their level
of immunity and significantly gain weight. Our findings
on growth recovery provide further evidence on the
benefits of early initiation of ART. Recent reports by
Shiau et al suggest that growth recovery is faster among
young infants compared to older children [16].
Compared to participants of the CHER study [7], in-
fants in our cohort were enrolled into care at an older
age, and were started on ART after several weeks of
delay. This may have partly contributed to the mortality
and loss to follow up seen before ART initiation. Thehile on antiretroviral therapy at Baylor-Uganda clinic









D4T-3TC-NVP 1.7 Oral Candidiasis
D4T-3TC-NVP 5.3 Malnutrition
= Lamivudine; ABC= Abacavir; NVP= Nevirapine.
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able reduction in ART initiation delay, with much youn-
ger infants being enrolled into care. The implementation
of the 2010 treatment guidelines together with the in-
creased adoption of strategies for early infant diagnosis
(EID) across Uganda and other parts of Africa, are likely
to lead to further reduction in ART initiation delays and
early enrollment of infants into care.
Among several cohorts of HIV-infected African chil-
dren currently undergoing treatment, viral suppression
within the first 6 months of ART has been reported in
60% to 89% of patients [17-21]. Our results, though
purely from infants, are in agreement with results from
these studies. Studies conducted in Europe and primarily
focusing on infants have reported much lower responses
to therapy [22].
In all patients on ART, the initial rapid attainment of
viral suppression is critical for the long term success of
treatment. Viral suppression permits immune recovery
and often delays the development of viral resistance
[20]. Persistence of HIV viremia among patients on ART
leads to early development of viral resistance ultimately
leading to treatment failure. With the achievement of
viral suppression, immune recovery and clinical im-
provement often occur. However, attainment of HIV
viral suppression and immune rebound is often depen-
dent on several factors including; the choice of ART
regimen, prior treatment or exposure to antiretroviral
drugs for PMTCT, adherence to medication, drug dos-
age, concurrent use of other drugs, presence of other in-
fections and a host of other factors [23-25]. Our study
did not assess all these factors; however, among baseline
variables measured, we did not find any associations
between infant characteristics and viral suppression.
Neither was there any association between viral suppres-
sion and ART regimen used. Viral suppression was seen
irrespective of age, sex, WHO clinical stage or baseline
CD4 cell counts.
The immune recovery that occurred in our cohort was
remarkable. The change from a baseline mean of 22% to
30% after 6 months of ART compares favorably with re-
sults seen among cohorts of children receiving treatment
elsewhere in Africa [5]. In general, the increase in CD4
cell count continued even during the second year of
therapy.
Despite this general success in treatment, several
children failed to attain viral suppression, even after
6-12 month of first-line treatment. We presume that
these children may have been infected with mutant re-
sistant viruses from mothers that were already on treat-
ment with first-line ART. Though HIV resistance tests
were not carried out, our conclusion is that these
children may have been cases of primary HIV resistance,
or cases of resistance resulting from prior use ofantiretroviral agents for PMTCT. Once switched to sec-
ond line ART, viral suppression was quickly attained.
These results are worrying since it implies that either
the mothers on treatment are passing on resistant virus
to their infants, or prior administration of PMTCT
medication to infants maybe contributing to the devel-
opment of viral resistance. This development further
limits the treatment options available for these chil-
dren. With more adults accessing and failing first-line
ART, these results underscore the need for HIV re-
sistance testing among HIV-infected infants born to
such adults.
The viral rebound that occurred in 7 patients after ini-
tial suppression may have been due to early viral resist-
ance or due to poor adherence to medication at the time
the viral load tests were carried out.
We noted a high level of acute and chronic malnutri-
tion in this cohort and this may have been due to a com-
bination of clinical and social factors that ultimately led
to reduced caloric intake, reduced absorption and in-
creased loss of nutrients needed for growth. This high
prevalence of malnutrition underscores the need for an
integrated HIV treatment approach that incorporates in-
terventions focusing on reducing malnutrition.
As reported in previous studies [21,26], deaths were
mainly reported in the first 6 months of ART. Early
deaths in HIV-infected children are often a result of
overwhelming infections in a setting of severe immuno-
deficiency and malnutrition [27,28]. Due to the rapid
progression of disease and the delays in diagnosis, many
infants enroll for medical care when infection, malnutri-
tion and severe immunodeficiency have set in. For such
patients, death occurs before the beneficial effects of
ART are realized. Mortality rates reported from several
African cohorts vary considerably; in 2 South African
cohorts, rates of 4.2 deaths per 100 child years [21] and
43.7 deaths per 1000 child-years were reported [5]. In
Kenya, 8.4 deaths/100 child-years were seen [29] and in
Zambia 6.94 deaths per 100 person years were reported
[30]. The mortality rate of 4.09 deaths per 100 child-
years seen in our cohort compares favorably with these
results.
Our study had several limitations: We were not able to
accurately document PMTCT history; neither were we
able to carry out HIV resistance testing. In addition, we
were unable to carry out postmortem examination of pa-
tients that died, and we did not measure adherence to
medication though it was emphasized at every clinic
visit. Despite these limitations and the possibility of fail-
ing to detect significant differences due to the small
sample size, the results presented here draw attention to
a vulnerable group of HIV-infected children and high-
light the feasibility of treatment success even in resource
constraint settings.
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Our results indicate that despite the high prevalence of
malnutrition and the probable transmission of resistant
virus from mothers to infants, treatment success for
HIV-infected infants living in resource-constrained set-
tings is possible. We recommend an integrated approach
to early infant diagnosis and treatment that takes into
consideration early detection of viral resistance espe-
cially among infants whose mothers received ART dur-
ing pregnancy and a robust nutritional intervention plan
for every infant.
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